BACKGROUND: Several lines of evidence link cannabinoid (CB) type 1 (CB (1) ) receptor-mediated endogenous CB (eCB) signaling to the etiology of alcohol dependence (AD). However, to date, only peripheral measures of eCB function have been collected in living humans with AD and no human in vivo data on the potentially critical role of the brain CB (1) receptor in AD have been published. This is an important gap in the literature, because recent therapeutic developments suggest that these receptors could be targeted for the treatment for AD. METHODS: Medication-free participants were scanned during early abstinence 4 weeks after their last drink. Using positron emission tomography (PET) with a high-resolution research tomograph and the CB (1) receptor selective radiotracer [(11) C]OMAR, we determined [(11) C]OMAR volume of distribution ( V (T) ) values, a measure of CB (1) receptor density, in a priori selected brain regions in men with AD (n = 8, age 37.4 ± 7.9 years; 5 smokers) and healthy control (HC) men (n = 8, age 32.5 ± 6.9 years; all nonsmokers). PET images reconstructed using the MOLAR algorithm with hardware motion correction were rigidly aligned to the subject-specific magnetic resonance (MR) image, which in turn was warped to an MR template. Time-activity curves (TACs) were extracted from the dynamic PET data using a priori selected regions of interest delineated in the MR template space. RESULTS: In AD relative to HC, [(11) C]OMAR V (T) values were elevated by approximately 20% (p = 0.023) in a circuit, including the amygdala, hippocampus, putamen, insula, anterior and posterior cingulate cortices, and orbitofrontal cortex. Age, body mass index, or smoking status did not influence the outcome. CONCLUSIONS: These findings agree with preclinical evidence and provide the first, albeit still preliminary in vivo evidence suggesting a role for brain CB (1) receptors in AD. The current study design does not answer the important question of whether elevated CB (1) receptors are a preexisting vulnerability factor for AD or whether elevations develop as a consequence of AD.
BACKGROUND: Several lines of evidence link cannabinoid (CB) type 1 (CB (1) ) receptor-mediated endogenous CB (eCB) signaling to the etiology of alcohol dependence (AD). However, to date, only peripheral measures of eCB function have been collected in living humans with AD and no human in vivo data on the potentially critical role of the brain CB (1) receptor in AD have been published. This is an important gap in the literature, because recent therapeutic developments suggest that these receptors could be targeted for the treatment for AD. METHODS: Medication-free participants were scanned during early abstinence 4 weeks after their last drink. Using positron emission tomography (PET) with a high-resolution research tomograph and the CB (1) receptor selective radiotracer [(11) C]OMAR, we determined [(11) C]OMAR volume of distribution ( V (T) ) values, a measure of CB (1) receptor density, in a priori selected brain regions in men with AD (n = 8, age 37.4 ± 7.9 years; 5 smokers) and healthy control (HC) men (n = 8, age 32.5 ± 6.9 years; all nonsmokers). PET images reconstructed using the MOLAR algorithm with hardware motion correction were rigidly aligned to the subject-specific magnetic resonance (MR) image, which in turn was warped to an MR template. Time-activity curves (TACs) were extracted from the dynamic PET data using a priori selected regions of interest delineated in the MR template space. RESULTS: In AD relative to HC, [(11) C]OMAR V (T) values were elevated by approximately 20% (p = 0.023) in a circuit, including the amygdala, hippocampus, putamen, insula, anterior and posterior cingulate cortices, and orbitofrontal cortex. Age, body mass index, or smoking status did not influence the outcome. CONCLUSIONS: These findings agree with preclinical evidence and provide the first, albeit still preliminary in vivo evidence suggesting a role for brain CB (1) receptors in AD. The current study design does not answer the important question of whether elevated CB (1) receptors are a preexisting vulnerability factor for AD or whether elevations develop as a consequence of AD.
Authors: Garth E Terry; Jeih-San Liow; Sami S Zoghbi; Jussi Hirvonen; Amanda G Farris; Alicja Lerner; Johannes T Tauscher; John M Schaus; Lee Phebus; Christian C Felder; Cheryl L Morse; Jinsoo S Hong; Victor W Pike; Christer Halldin; Robert B Innis Journal: Neuroimage Date: 2009-06-30 Impact factor: 6.556
Authors: Koen Van Laere; Karolien Goffin; Cindy Casteels; Patrick Dupont; Luc Mortelmans; Jan de Hoon; Guy Bormans Journal: Neuroimage Date: 2007-11-13 Impact factor: 6.556
Authors: K Yaragudri Vinod; Ratnakumar Yalamanchili; Panayotis K Thanos; Csaba Vadasz; Thomas B Cooper; Nora D Volkow; Basalingappa L Hungund Journal: Synapse Date: 2008-08 Impact factor: 2.562
Authors: H Donald Burns; Koen Van Laere; Sandra Sanabria-Bohórquez; Terence G Hamill; Guy Bormans; Wai-si Eng; Ray Gibson; Christine Ryan; Brett Connolly; Shil Patel; Stephen Krause; Amy Vanko; Anne Van Hecken; Patrick Dupont; Inge De Lepeleire; Paul Rothenberg; S Aubrey Stoch; Josee Cote; William K Hagmann; James P Jewell; Linus S Lin; Ping Liu; Mark T Goulet; Keith Gottesdiener; John A Wagner; Jan de Hoon; Luc Mortelmans; Tung M Fong; Richard J Hargreaves Journal: Proc Natl Acad Sci U S A Date: 2007-05-29 Impact factor: 11.205
Authors: Nikos Makris; Marlene Oscar-Berman; Sharon Kim Jaffin; Steven M Hodge; David N Kennedy; Verne S Caviness; Ksenija Marinkovic; Hans C Breiter; Gregory P Gasic; Gordon J Harris Journal: Biol Psychiatry Date: 2008-03-28 Impact factor: 13.382
Authors: Dagmar Koethe; Andrea Giuffrida; Daniela Schreiber; Martin Hellmich; Frauke Schultze-Lutter; Stefan Ruhrmann; Joachim Klosterkötter; Daniele Piomelli; F Markus Leweke Journal: Br J Psychiatry Date: 2009-04 Impact factor: 9.319
Authors: Florence P Varodayan; Michal Bajo; Neeraj Soni; George Luu; Samuel G Madamba; Paul Schweitzer; Marisa Roberto Journal: Addict Biol Date: 2016-01-20 Impact factor: 4.280
Authors: Christine DeLorenzo; Nicole DellaGioia; Michael Bloch; Gerard Sanacora; Nabeel Nabulsi; Chadi Abdallah; Jie Yang; Ruofeng Wen; J John Mann; John H Krystal; Ramin V Parsey; Richard E Carson; Irina Esterlis Journal: Biol Psychiatry Date: 2014-07-10 Impact factor: 13.382
Authors: Marc D Normandin; Ming-Qiang Zheng; Kuo-Shyan Lin; N Scott Mason; Shu-Fei Lin; Jim Ropchan; David Labaree; Shannan Henry; Wendol A Williams; Richard E Carson; Alexander Neumeister; Yiyun Huang Journal: J Cereb Blood Flow Metab Date: 2015-04-01 Impact factor: 6.200
Authors: Robert H Pietrzak; Yiyun Huang; Stefani Corsi-Travali; Ming-Qiang Zheng; Shu-fei Lin; Shannan Henry; Marc N Potenza; Daniele Piomelli; Richard E Carson; Alexander Neumeister Journal: Neuropsychopharmacology Date: 2014-05-12 Impact factor: 7.853
Authors: Mohini Ranganathan; Jose Cortes-Briones; Rajiv Radhakrishnan; Halle Thurnauer; Beata Planeta; Patrick Skosnik; Hong Gao; David Labaree; Alexander Neumeister; Brian Pittman; Toral Surti; Yiyun Huang; Richard E Carson; Deepak Cyril D'Souza Journal: Biol Psychiatry Date: 2015-08-29 Impact factor: 13.382
Authors: Oleg Sadovski; Justin W Hicks; Jun Parkes; Roger Raymond; José Nobrega; Sylvain Houle; Mariateresa Cipriano; Christopher J Fowler; Neil Vasdev; Alan A Wilson Journal: Bioorg Med Chem Date: 2013-05-07 Impact factor: 3.641